公开(公告)号：WO2005117989A9

公开(公告)日：2006-02-02

申请号：PCT/EP2005005992

申请日：2005-06-03

Applicant: CENTRE NAT RECH SCIENT ,  UNIV PARIS CURIE ,  UNIV MONTPELLIER II ,  SITBON NAOMI ,  KLATZMANN DAVID ,  MONGELLAZ CEDRIC ,  ADJALI OUMEYA ,  JACQUET CHANTAL ,  STEINBERG MARCOS ,  MARODON GILLES

Inventor： SITBON NAOMI ,  KLATZMANN DAVID ,  MONGELLAZ CEDRIC ,  ADJALI OUMEYA ,  JACQUET CHANTAL ,  STEINBERG MARCOS ,  MARODON GILLES

IPC: H01B7/295 ,  A61K38/11 ,  A61K38/28 ,  A61K38/45 ,  A61K48/00 ,  C07K14/11 ,  C12N5/06 ,  C12N15/867 ,  C12N15/90 ,  H01B3/44 ,  H01B7/02 ,  C12N5/10

CPC classification number: A61K48/0075 ,  A61K38/00 ,  A61K38/28 ,  A61K38/45 ,  A61K2039/5256 ,  A61K2039/57 ,  C07K14/005 ,  C12N15/86 ,  C12N15/90 ,  C12N2740/16043 ,  C12N2760/16122 ,  C12N2830/00 ,  C12N2830/008 ,  C12N2830/48 ,  C12N2830/50 ,  C12N2840/203 ,  H01B3/441 ,  H01B7/295

Abstract: The invention relates to the use of viral vectors able to stably integrate into the genome of thymic stromal cells, or of intrathymic lymphocytes or lymphocytes precursors, for the manufacture of a medicine intended for intrathymic administration in the frame of the prevention or treatment of genetic immunodeficiencies, acquired immunodeficiencies, or for the induction of immune tolerance of the organism to self or non-self gene products, cells or tissues, or for the prevention or treatment of autoimmune diseases.

Abstract translation: 本发明涉及能够稳定地整合到胸腺基质细胞或胸腺内淋巴细胞或淋巴细胞前体的基因组中的病毒载体在预防或治疗基因免疫缺陷的框架中用于制造用于胸腺内给药的药物的用途 ，获得性免疫缺陷，或诱导生物体对自身或非自身基因产物，细胞或组织的免疫耐受，或用于预防或治疗自身免疫性疾病。

公开(公告)号：WO02057810A2

公开(公告)日：2002-07-25

申请号：PCT/FR0200210

申请日：2002-01-18

Applicant: CENTRE NAT RECH SCIENT ,  UNIV MONTPELLIER II ,  ETIENNE PASCAL

Inventor： ETIENNE PASCAL

IPC: G02B6/13 ,  G02B6/132 ,  G02B

CPC classification number: G02B6/13 ,  G02B6/132

Abstract: The invention relates to a method for manufacturing a waveguide component with several layers stacked on a silicon substrate. Said component comprises a buffer layer (2) which is positioned on said substrate (1), a guiding layer (3) which is positioned on the buffer layer and which is used to produce a waveguide device (6), and an outer layer (5) used as protection against external stresses. The layers are made from an organic-inorganic hybrid using the sol-gel process. The inventive method is characterised in that an additional layer (4) is disposed on top of the guiding layer (3) in such a way that a symmetrical structure is obtained having the same refractive index around the waveguide device produced in the guiding layer (3). The invention can be used to produce a waveguide component.

Abstract translation: 本发明涉及一种用于制造具有堆叠在硅衬底上的多层的波导部件的方法。 所述部件包括位于所述基板（1）上的缓冲层（2），位于缓冲层上并用于制造波导器件（6）的引导层（3）和外层 5）用作外部应力的保护。 这些层使用溶胶 - 凝胶法由有机 - 无机杂化物制成。 本发明的方法的特征在于，附加层（4）设置在引导层（3）的顶部上，使得获得具有在引导层（3）中产生的波导器件周围相同折射率的对称结构 ）。 本发明可用于制造波导部件。

公开(公告)号：WO2012104505A8

公开(公告)日：2013-09-19

申请号：PCT/FR2012000040

申请日：2012-01-31

Applicant: UNIV MONTPELLIER II ,  ARINERO RICHARD ,  MEKKI JULIEN ,  TOUBOUL ANTOINE ,  SAIGNE FREDERIC ,  VAILLE JEAN-ROCH

Inventor： ARINERO RICHARD ,  MEKKI JULIEN ,  TOUBOUL ANTOINE ,  SAIGNE FREDERIC ,  VAILLE JEAN-ROCH

IPC: G01T1/02

CPC classification number: G01T1/026

Abstract: A method of measuring a dose related to the non-ionizing effects of a radiation of particles comprises the irradiation of a capacitive element furnished with an electrode made of a semiconducting material, the measurement of the capacitance of the capacitive element in an accumulation regime and the determination of the dose related to the non-ionizing effects on the basis of the measurement of capacitance of the capacitive element in the accumulation regime.

Abstract translation: 测量与颗粒辐射的非电离效应有关的剂量的方法包括：照射具有由半导体材料制成的电极的电容元件，电容元件在积聚状态下的电容的测量和 基于在积聚状态下的电容元件的电容的测量，确定与非电离效应相关的剂量。

公开(公告)号：WO2012052629A3

公开(公告)日：2012-06-14

申请号：PCT/FR2011000559

申请日：2011-10-18

Applicant: CENTRE NAT RECH SCIENT ,  UNIV MONTPELLIER II ,  BLANCHARD JEAN-MARIE ,  LEMMERS BENEDICTE ,  BENDRIS NAWAL ,  ARSIC NIKOLA

Inventor： BLANCHARD JEAN-MARIE ,  LEMMERS BENEDICTE ,  BENDRIS NAWAL ,  ARSIC NIKOLA

IPC: G01N33/574 ,  A61K38/17

CPC classification number: G01N33/574 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N2333/4739

Abstract: The invention relates to Cyc A2 for use as a specific biomarker of the invasive capacity of cancer cells of human or animal origin and to a method for evaluating the invasive power of cancer cells. Use as medicaments and for the screening of anti-metastatic compounds.

Abstract translation: 本发明涉及用作人或动物来源的癌细胞的侵入能力的特异性生物标志物的Cyc A2和用于评估癌细胞侵袭力的方法。 用作药物和筛选抗转移性化合物。

公开(公告)号：WO2005023255A3

公开(公告)日：2006-04-20

申请号：PCT/FR2004002261

申请日：2004-09-06

Applicant: CENTRE NAT RECH SCIENT ,  UNIV MONTPELLIER II ,  INST CURIE ,  TAZI JAMAL ,  SORET JOHANN ,  JEANTEUR PHILIPPE ,  GRIERSON DAVID

Inventor： TAZI JAMAL ,  SORET JOHANN ,  JEANTEUR PHILIPPE ,  GRIERSON DAVID

IPC: A61K31/4745 ,  A61K31/403 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/475 ,  A61K31/496 ,  A61K31/5377 ,  A61P11/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07D209/80 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

CPC classification number: A61K31/4375 ,  A61K31/403 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377 ,  C07D209/80 ,  C07D471/04 ,  C07D471/14

Abstract: The invention relates to indole-derived compounds and to the use of said compounds for the preparation of a medicament that can be used to treat diseases related to the process of splicing pre-messenger RNAs in the cell, such as Frasier syndrome, frontotemporal dementia linked to chromosome 17 (a form of Parkinson's disease), Leigh syndrome (a type of encephalopathy), atypical cystic fibrosis, certain neuropathologies including Alzheimer's disease linked to a mutation in the Tau protein, muscle atrophy which affects the SMN (Survival of Motor Neuron) gene, depression linked to a serotonin splicing impairment, and certain cancers in which the global splicing process is affected (e.g. breast cancer, colon cancer and certain lymphomas), as well as viral diseases such as AIDS.

Abstract translation: 本发明涉及吲哚衍生的化合物和所述化合物用于制备药物的用途，所述药物可用于治疗与剪接细胞中的前信使RNA的过程相关的疾病，例如Frasier综合征，额颞额痴呆 到17号染色​​体（帕金森病的一种形式），Leigh综合征（一种脑病），非典型囊性纤维化，某些神经病理学包括与Tau蛋白突变有关的阿尔茨海默氏病，影响SMN的肌肉萎缩（运动神经元的存活） 基因，与血清素剪接损伤相关的抑郁症，以及影响全球剪接过程的某些癌症（例如乳腺癌，结肠癌和某些淋巴瘤）以及病毒性疾病如艾滋病。

公开(公告)号：WO2005009418A2

公开(公告)日：2005-02-03

申请号：PCT/IB2004002703

申请日：2004-07-26

Applicant: IDENIX CAYMAN LTD ,  CENTRE NAT RECH SCIENT ,  UNIV MONTPELLIER II ,  STORER RICHARD ,  GOSSELIN GILLES ,  DUKHAN DAVID ,  LEROY FREDERIC

Inventor： STORER RICHARD ,  GOSSELIN GILLES ,  DUKHAN DAVID ,  LEROY FREDERIC

IPC: A61K31/00 ,  A61K31/706 ,  A61P31/14 ,  C07H19/044 ,  C07H19/052 ,  C07H19/056

CPC classification number: A61K31/706 ,  A61K31/00 ,  A61K45/06 ,  C07H19/04 ,  C07H19/044 ,  C07H19/052 ,  C07H19/056 ,  C07H19/23

Abstract: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

Abstract translation: 本发明涉及用于治疗感染丙型肝炎，黄病毒和/或瘟病毒的宿主，特别是人的方法，包括向该宿主施用有效量的抗HCV生物活性戊呋喃核苷，其中戊呋喃核苷碱基是任选的 取代的2-氮杂嘌呤。 任选取代的五氟鸟苷或其盐或前药可以单独施用或与一种或多种任选取代的五氟鸟苷或其它抗病毒剂组合施用。

公开(公告)号：WO2004091032A2

公开(公告)日：2004-10-21

申请号：PCT/FR2004000797

申请日：2004-03-30

Applicant: COMMISSARIAT ENERGIE ATOMIQUE ,  UNIV MONTPELLIER II ,  CENTRE NAT RECH SCIENT ,  ELECTRICITE DE FRANCE ,  MORIN ARNAUD ,  GAUTIER LUDMILA ,  DEABATE STEPHANO ,  JONES DEBORAH ,  ROZIERE JACQUES ,  MOSDALE RENAUT

Inventor： MORIN ARNAUD ,  GAUTIER LUDMILA ,  DEABATE STEPHANO ,  JONES DEBORAH ,  ROZIERE JACQUES ,  MOSDALE RENAUT

IPC: C08K3/38 ,  H01M8/10

CPC classification number: H01M8/1048 ,  C08K3/38 ,  H01M8/1027 ,  H01M8/103 ,  H01M8/1032 ,  H01M8/1074 ,  H01M8/1081 ,  H01M8/109 ,  Y02P70/56

Abstract: A composite material made of borophosphosilicate and an organic matrix, used to create, preferably, a solid electrolyte membrane for a proton conduction electrochemical device having an operating temperature of up to 400 DEG C. The organic matrix consists of a thermally stable polymer. The polymer can, for example, be a polyimide.

Abstract translation: 由硼磷硅酸盐和有机基质制成的复合材料，用于制造优选用于质子传导电化学装置的固体电解质膜，其操作温度高达400℃。有机基质由热稳定的聚合物组成。 聚合物可以是例如聚酰亚胺。